Menu
Search
|

Menu

Close
X

Vivus Inc VVUS.OQ (NASDAQ Stock Exchange Global Select Market)

3.33 USD
-0.10 (-2.92%)
As of 3:59 PM EST
chart
Previous Close 3.43
Open 3.42
Volume 16,381
3m Avg Volume 14,805
Today’s High 3.42
Today’s Low 3.27
52 Week High 9.88
52 Week Low 3.27
Shares Outstanding (mil) 10.63
Market Capitalization (mil) 36.46
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
45
FY17
65
FY16
124
FY15
95
EPS (USD)
FY18
-3.058
FY17
-2.853
FY16
2.085
FY15
-8.964
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
0.64
15.43
Price to Book (MRQ)
vs sector
--
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
--
14.84
LT Debt to Equity (MRQ)
vs sector
--
11.13
Return on Investment (TTM)
vs sector
-16.91
12.77
Return on Equity (TTM)
vs sector
--
14.47

EXECUTIVE LEADERSHIP

David Norton
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Kenneth Suh
President, Since 2018
Salary: --
Bonus: --
John Amos
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Mark Oki
Chief Financial Officer, Chief Accounting Officer, Since 2015
Salary: $350,000.00
Bonus: --
M. Oehrlein
Chief Operations Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

900 E Hamilton Ave Ste 550
CAMPBELL   CA   95008-0643

Phone: +1650.9345200

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

SPONSORED STORIES